Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind placebo- and active-controlled study of oral piclidenoson in moderate-to-severe plaque psoriasis
MOH_2018-06-03_002429Phase 3Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piclidenoson in plaque psoriasis (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: PASI 75 at week 16 and Safety of oral piclidenoson. Started May 2018; status: completed.
02
Drugs
piclidenoson
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2018-06-03_002429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-03_002429.